Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
GLP-1 Pipeline In November 2023, the FDA approved Zepbound (tirzepatide), a GLP-1 antagonist and GIP dual agonist with superior weight loss efficacy compared to its competitors
Authors included David D
This extended feeling of fullness naturally leads you to eat less throughout the day
In the STEP 1 trial, semaglutide led to an average 14.9% reduction in body weight over 68 weeks , far outperforming placebo (NEJM study on semaglutide for weight loss)
Additionally, the absence of evidence of delayed stomach emptying shows that the drug has no negative effects on the digestive system, which is crucial to take into account when assessing the efficacy and safety of weight-loss drugs
Conclusion GLP-1s directly influence bone remodeling through receptor expression on osteocytes and bone mesenchymal stem cells
